Total Payments
$30,973
2024 Payments
$806.60
Companies
55
Transactions
718
Medicare Patients
4,662
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$16,095 (52.0%)
Food & Beverage$13,823 (44.6%)
Travel$789.24 (2.5%)
Consulting$125.00 (0.4%)
Research$125.00 (0.4%)
Education$15.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,095 | 10 | 52.0% |
| Food and Beverage | $13,823 | 700 | 44.6% |
| Travel and Lodging | $789.24 | 4 | 2.5% |
| Unspecified | $125.00 | 1 | 0.4% |
| Consulting Fee | $125.00 | 1 | 0.4% |
| Education | $15.46 | 2 | 0.0% |
Payments by Type
General
$30,848
717 transactions
Research
$125.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Depomed, Inc. | $11,975 | 26 | $0 (2017) |
| Collegium Pharmaceutical, Inc. | $7,127 | 106 | $0 (2024) |
| Abbott Laboratories | $2,281 | 113 | $0 (2024) |
| Egalet US Inc | $994.99 | 89 | $0 (2018) |
| Daiichi Sankyo Inc. | $952.82 | 38 | $0 (2019) |
| ABBVIE INC. | $904.32 | 46 | $0 (2024) |
| PFIZER INC. | $651.16 | 28 | $0 (2024) |
| Indivior Inc. | $625.76 | 14 | $0 (2022) |
| Pernix Therapeutics Holdings, Inc. | $576.09 | 26 | $0 (2018) |
| Gilead Sciences, Inc. | $380.76 | 18 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $806.60 | 31 | ABBVIE INC. ($292.14) |
| 2023 | $1,003 | 34 | Vertos Medical, Inc. ($279.17) |
| 2022 | $1,681 | 83 | Abbott Laboratories ($563.08) |
| 2021 | $1,657 | 81 | Abbott Laboratories ($391.64) |
| 2020 | $836.17 | 53 | Abbott Laboratories ($306.27) |
| 2019 | $1,249 | 56 | Indivior Inc. ($365.37) |
| 2018 | $2,288 | 108 | Pernix Therapeutics Holdings, Inc. ($386.60) |
| 2017 | $21,451 | 272 | Depomed, Inc. ($11,975) |
All Payment Transactions
718 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.18 | General |
| Category: Opioid Analgesic | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Gastroenterology | ||||||
| 10/22/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Neuromodulation | ||||||
| 10/18/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.12 | General |
| Category: Opioid Analgesic | ||||||
| 09/30/2024 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Spinal Cord Stimulator | ||||||
| 08/28/2024 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $129.81 | General |
| Category: Spinal Cord Stimulator | ||||||
| 08/27/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/21/2024 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Spinal Cord Stimulator | ||||||
| 08/19/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Neuromodulation | ||||||
| 08/15/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.73 | General |
| Category: Opioid Analgesic | ||||||
| 08/08/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: NEUROSCIENCE | ||||||
| 07/26/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $4.15 | General |
| Category: Opioid Analgesic | ||||||
| 07/16/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $5.40 | General |
| Category: Opioid Analgesic | ||||||
| 06/17/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: PAIN | ||||||
| 06/11/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.68 | General |
| Category: Opioid Analgesic | ||||||
| 05/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: NEUROSCIENCE | ||||||
| 05/07/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Insomnia | ||||||
| 04/18/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.69 | General |
| Category: Opioid Analgesic | ||||||
| 04/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $9.44 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 03/12/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Analgesic | ||||||
| 03/08/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $18.73 | General |
| Category: Opioid Analgesic | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber Knowledge, Attitudes and Behavior about SUBOXONE buprenorphine and naloxone Sublingual Film CIII Safety and Use Information | Indivior Inc. | $125.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 907 | 2,224 | $944,128 | $179,287 |
| 2022 | 16 | 1,121 | 3,425 | $1.4M | $277,865 |
| 2021 | 23 | 1,289 | 3,638 | $1.4M | $287,579 |
| 2020 | 22 | 1,345 | 3,868 | $1.7M | $311,217 |
Total Patients
4,662
Total Services
13,155
Medicare Billing
$1.1M
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 181 | 626 | $352,438 | $55,076 | 15.6% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 80 | 122 | $109,800 | $23,939 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 147 | 305 | $116,815 | $20,745 | 17.8% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Office | 2023 | 41 | 70 | $69,580 | $14,458 | 20.8% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 24 | 26 | $56,576 | $13,278 | 23.5% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 81 | 122 | $55,510 | $13,112 | 23.6% |
| 64491 | Injection of upper or middle spine facet joint using imaging guidance, second level | Office | 2023 | 40 | 67 | $33,098 | $7,572 | 22.9% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 23 | 24 | $21,456 | $7,014 | 32.7% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 19 | 21 | $24,003 | $5,064 | 21.1% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 24 | 31 | $25,978 | $4,312 | 16.6% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 129 | 618 | $16,130 | $3,791 | 23.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $22,568 | $2,964 | 13.1% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2023 | 19 | 21 | $9,681 | $2,568 | 26.5% |
| 64479 | Injection of anesthetic and/or steroid drug into upper or middle spine nerve root using imaging guidance, single level | Office | 2023 | 11 | 11 | $13,596 | $2,251 | 16.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 18 | 28 | $9,184 | $1,508 | 16.4% |
| 64480 | Injection of anesthetic and/or steroid drug into upper or middle spine nerve root using imaging guidance, each additional level | Office | 2023 | 11 | 11 | $6,556 | $1,338 | 20.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 19 | 19 | $475.00 | $234.65 | 49.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 14 | 76 | $684.00 | $64.14 | 9.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 180 | 764 | $430,132 | $71,679 | 16.7% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2022 | 101 | 196 | $176,400 | $41,109 | 23.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 181 | 618 | $236,694 | $40,700 | 17.2% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2022 | 100 | 196 | $89,180 | $22,154 | 24.8% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2022 | 50 | 77 | $88,011 | $20,186 | 22.9% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2022 | 28 | 36 | $78,336 | $19,199 | 24.5% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Office | 2022 | 49 | 78 | $77,532 | $16,211 | 20.9% |
About Dr. Bart Gatz, M.D
Dr. Bart Gatz, M.D is a Pain Medicine healthcare provider based in Greenacres, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801819206.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bart Gatz, M.D has received a total of $30,973 in payments from pharmaceutical and medical device companies, with $806.60 received in 2024. These payments were reported across 718 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($16,095).
As a Medicare-enrolled provider, Gatz has provided services to 4,662 Medicare beneficiaries, totaling 13,155 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Location Greenacres, FL
- Active Since 07/26/2006
- Last Updated 01/23/2024
- Taxonomy Code 207LP2900X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1801819206
Products in Payments
- Nucynta (Drug) $11,975
- Xtampza ER (Drug) $6,077
- XTAMPZA (Drug) $950.83
- Proclaim Family of SCS IPGs (Device) $790.82
- Morphabond ER (Drug) $677.99
- PROCLAIM (Device) $595.06
- ZOHYDRO ER (Drug) $576.09
- ARYMO ER (Drug) $515.72
- SUBLOCADE (Drug) $445.03
- UBRELVY (Drug) $431.11
- SPRIX (Drug) $388.35
- Proclaim IPG (Device) $375.58
- SCS IPGs (Device) $369.79
- BOTOX (Biological) $354.40
- NURTEC ODT (Drug) $353.51
- QULIPTA (Drug) $335.04
- SiJoin (Device) $316.06
- Movantik (Drug) $292.52
- mild Device Kit (Device) $279.17
- LYRICA (Drug) $276.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.